CLDX | tickerfilter.com

Fundamental analysis

16%

Profitability 0%

Dept financing 5%

Liquidity 75%

Performance 20%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0.72%

1 Month

-1.81%

3 Months

-20.51%

6 Months

-30.03%

1 Year

-47.11%

2 Year

-37.75%

Key data

Stock price

$19.57

P/E Ratio

0.00

DAY RANGE

$18.91 - $19.65

EPS

-$2.45

52 WEEK RANGE

$14.40 - $47.00

52 WEEK CHANGE

-$47.11

MARKET CAP

1.677 B

YIELD

N/A

SHARES OUTSTANDING

66.288 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-05-2025

BETA

0.76

PUBLIC FLOAT

AVERAGE 10 VOLUME

$520,628

AVERAGE 30 VOLUME

$865,058

Company detail

CEO: Anthony S. Marucci
Region: US
Website: celldex.com
Employees: 150
IPO year: 1990

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing

Celldex Therapeutics, Inc. engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27.

CLDX - Celldex Therapeutics, Inc.